Profound Medical (PROF)
(Delayed Data from NSDQ)
$7.86 USD
-0.04 (-0.51%)
Updated May 23, 2024 10:34 AM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
PROF 7.86 -0.04(-0.51%)
Will PROF be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PROF based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PROF
Profound Medical (PROF) Adds AI to Prostate Cancer Treatment
ElectroCore, Inc. (ECOR) Reports Q1 Loss, Tops Revenue Estimates
PROF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Profound Medical (PROF), Siemens Unite to Treat Prostate Cancer
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates
Profound Medical (PROF) Soars 9.4%: Is Further Upside Left in the Stock?
Other News for PROF
Profound Medical Shareholders Back Board and Auditor
Profound Medical Annual General Meeting of Shareholders Voting Results
Profound Medical Shareholders Approve All Resolutions
Profound Medical gets FDA okay for TULSA AI module
Profound Medical’s AI Tool Streamlines Prostate Therapy